Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
$10.49
$11.14
$9.76
$19.22
$298.20M0.85381,591 shs149,152 shs
Fonar Corporation stock logo
FONR
Fonar
$15.98
+0.6%
$15.51
$12.00
$17.98
$98.51M0.9614,230 shs6,777 shs
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$9.15
+0.4%
$9.39
$5.45
$18.98
$301.37M1.89210,708 shs138,186 shs
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
$33.66
-0.2%
$28.50
$23.53
$39.08
$300.28M1.2642,606 shs17,160 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
0.00%-1.96%-1.59%-11.18%-16.48%
Fonar Corporation stock logo
FONR
Fonar
+0.63%+4.86%+1.33%+10.97%-7.79%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
+0.44%+1.78%+4.45%-29.51%+18.68%
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
-0.21%-0.85%+34.16%+18.48%-1.43%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
2.0669 of 5 stars
3.51.00.00.03.20.80.6
Fonar Corporation stock logo
FONR
Fonar
2.5045 of 5 stars
0.05.00.00.03.30.81.9
NeuroPace, Inc. stock logo
NPCE
NeuroPace
3.0015 of 5 stars
3.43.00.00.02.23.30.6
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
1.9775 of 5 stars
3.51.00.00.02.11.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
3.00
Buy$19.6787.48% Upside
Fonar Corporation stock logo
FONR
Fonar
0.00
N/AN/AN/A
NeuroPace, Inc. stock logo
NPCE
NeuroPace
2.83
Moderate Buy$16.6081.42% Upside
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
3.00
Buy$50.0048.54% Upside

Current Analyst Ratings Breakdown

Latest FONR, SMTI, CLPT, and NPCE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$53.00 ➝ $54.00
8/18/2025
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$53.00 ➝ $54.00
8/13/2025
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/13/2025
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$17.00 ➝ $15.00
8/1/2025
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$8.00 ➝ $9.00
(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
$31.39M9.50N/AN/A$0.69 per share15.20
Fonar Corporation stock logo
FONR
Fonar
$102.88M0.96$3.10 per share5.16$24.78 per share0.64
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$88.57M3.42N/AN/A$0.59 per share15.51
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
$86.67M3.46N/AN/A$3.98 per share8.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$18.91M-$0.81N/AN/AN/A-66.15%-94.44%-51.58%11/6/2025 (Estimated)
Fonar Corporation stock logo
FONR
Fonar
$10.57M$1.2512.78N/A8.19%5.31%3.97%9/26/2025 (Estimated)
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$27.14M-$0.84N/AN/AN/A-29.29%-168.61%-25.48%11/11/2025 (Estimated)
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
-$9.66M-$1.16N/AN/AN/A-10.22%-26.43%-10.69%11/11/2025 (Estimated)

Latest FONR, SMTI, CLPT, and NPCE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
-$0.33-$0.23+$0.10-$0.23$25.15 million$25.83 million
8/12/2025Q2 2025
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$0.20-$0.21-$0.01-$0.21$9.20 million$9.22 million
8/12/2025Q2 2025
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$0.24-$0.26-$0.02-$0.26$23.08 million$23.52 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
N/AN/AN/AN/AN/A
Fonar Corporation stock logo
FONR
Fonar
N/AN/AN/AN/AN/A
NeuroPace, Inc. stock logo
NPCE
NeuroPace
N/AN/AN/AN/AN/A
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
1.46
7.30
6.45
Fonar Corporation stock logo
FONR
Fonar
N/A
10.05
9.86
NeuroPace, Inc. stock logo
NPCE
NeuroPace
3.02
5.47
4.51
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
1.25
2.26
2.03

Institutional Ownership

CompanyInstitutional Ownership
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
30.08%
Fonar Corporation stock logo
FONR
Fonar
50.64%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
78.83%
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
8.10%

Insider Ownership

CompanyInsider Ownership
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
6.97%
Fonar Corporation stock logo
FONR
Fonar
1.55%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
20.50%
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
42.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
11028.43 million26.45 millionOptionable
Fonar Corporation stock logo
FONR
Fonar
4806.20 million6.11 millionNot Optionable
NeuroPace, Inc. stock logo
NPCE
NeuroPace
17033.08 million26.30 millionOptionable
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
608.90 million5.11 millionNot Optionable

Recent News About These Companies

Sanara Medtech Inc News (SMTI) - Investing.com
Q3 EPS Estimates for Sanara MedTech Lifted by HC Wainwright
HC Wainwright Forecasts Sanara MedTech Q1 Earnings
HC Wainwright Comments on Sanara MedTech Q1 Earnings
FY2025 EPS Estimates for Sanara MedTech Raised by Analyst
Sanara MedTech Sales Jump 28 Percent

New MarketBeat Followers Over Time

Media Sentiment Over Time

ClearPoint Neuro stock logo

ClearPoint Neuro NASDAQ:CLPT

$10.49 0.00 (0.00%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$10.59 +0.10 (+0.94%)
As of 08/29/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Fonar stock logo

Fonar NASDAQ:FONR

$15.98 +0.10 (+0.63%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$15.97 -0.01 (-0.04%)
As of 08/29/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates in two segments, Medical Equipment, and Physician Management and Diagnostic Services. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company also offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters, and development and implementation of practice growth and marketing strategies. It owns and operates diagnostic imaging facilities in Florida; and manages MRI scanning facilities. The company markets its scanners to private diagnostic imaging centers and hospital outpatient imaging facilities. FONAR Corporation was founded in 1970 and is based in Melville, New York.

NeuroPace stock logo

NeuroPace NASDAQ:NPCE

$9.15 +0.04 (+0.44%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$9.15 +0.00 (+0.05%)
As of 08/29/2025 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Sanara MedTech stock logo

Sanara MedTech NASDAQ:SMTI

$33.66 -0.07 (-0.21%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$33.64 -0.02 (-0.07%)
As of 08/29/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.